anti-CD3/undisclosed target 3 bispecific T-cell engager XPAT/Pro-XTEN (Amunix)

N/A

Report date: 2026/03/19 16:58:19

Base Information

Drug Nameanti-CD3/undisclosed target 3 bispecific T-cell engager XPAT/Pro-XTEN (Amunix)
Drug Alias NameXTENylated protease-activated T cell engager Pro-XTEN technology (Amunix)anti-CD3/undisclosed target 3 bispecific T-cell engager XPAT/Pro-XTEN (Sanofi)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAmunix Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofi
Inactive CompaniesAmunix Pharmaceuticals Inc
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A